Day: April 3, 2023

Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial

First patient treated in the feasibility and safety study of intratumoral diffusing alpha radiation emitters for the treatment of advanced inoperable pancreatic cancer. Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial First patient treated in the feasibility and safety study of intratumoral diffusing alpha radiation emitters for the treatment of advanced inoperable pancreatic cancer. JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with advanced inoperable pancreatic cancer has been treated in a feasibility and safety study of Alpha DaRT at the Jewish General...

Continue reading

Global Electric Vehicle Battery Market Size Worth USD 98.97 Billion, Globally, by 2029 at a CAGR of 10.5%

The global electric vehicle (EV) battery market size is projected to reach USD 98.97 billion in 2029, at CAGR of 10.5% during the forecast period. The global electric vehicle (EV) battery industry was valued at 37.91 billion in 2021. Pune, India., April 03, 2023 (GLOBE NEWSWIRE) — The global electric vehicle (EV) battery market size was valued at USD 37.91 billion in 2021. The market is projected to grow from USD 49.22 billion in 2022 to USD 98.97 billion by 2029, exhibiting a CAGR of 10.5% during the forecast period. The demand for electric car batteries is rising along with the demand for Electric Vehicles (EVs) around the world. Some of the key factors influencing the adoption of electric vehicles globally include government emphasis on rapid electrification to reduce reliance on imports of fossil fuels and to combat climate...

Continue reading

UAB “Atsinaujinančios Energetikos Investicijos” publishes its NAV for March 2023

At the end of March 2023, the net asset value (NAV) of UAB “Atsinaujinančios Energetikos Investicijos” including success fee-accrual increased to 107,257,120 EUR compared to the previously determined NAV at the end of December 2022, which amounted to EUR 103,538,263. The share price including success fee-accrual decreased to EUR 1.8690 compared to the previously determined share price which at the end of December 2022, amounted to EUR 1.8865. The pro-forma internal rate of return (IRR) since inception including success fee-accrual decreased to 13.23% compared to the previously announced IRR of December 2022, which amounted to 16.51%. At the end of March 2022, the NAV excluding success fee accrual increased to EUR 109,111,253 compared to the previously determined NAV at the end of December 2022, which amounted to EUR 106,042,079. The share...

Continue reading

ZyVersa Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results

Key Highlights: Closed business combination with Larkspur Health Acquisition Corp. in December 2022 and began trading on Nasdaq Global Market under the ticker symbol “ZVSA” Planning underway with nephrologists for an investigator-initiated clinical trial in focal segmental glomerulosclerosis (“FSGS”) and up to two other renal populations to gain human proof-of-concept for Cholesterol Efflux Mediator™ VAR 200 Recently published data in peer-reviewed journals detail the mechanism of action of inflammasome ASC inhibitor IC 100, and support its CNS activity in preclinical models of aging and Alzheimer’s disease Added three new Board members and three new members to Renal Scientific Advisory Board WESTON, Fla., April 03, 2023 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage...

Continue reading

Vista Bancshares, Inc. Completes Acquisition of Charis Holdings, Inc.

Vista Bank Dallas Corporate Headquarters Vista Bank’s corporate headquarters are located at 5840 W. Northwest Highway, near the intersection of the Dallas North Tollway in Preston Center. In addition executive offices, there is a full-service Banking Center on the first floor. Vista’s drive-through location is conveniently located around the corner off Preston Road in Highland Park. John D. Steinmetz, Vista Bank Chief Executive Officer Named Vice-Chairman of the holding company Vista Bancshares in 2018, John D. Steinmetz is laser-focused on continually increasing shareholder value. Since taking the helm, Steinmetz has ensured responsible, disciplined organic growth approaching 700% in the last decade. A 2022 DCEO Financial Executive Award Nominee for Outstanding Public Service, 2021 DCEO Dallas 500 recipient, 2019 Dallas...

Continue reading

From Grinding to Polishing: The Remarkable Evolution of Abrasive Tools Market

SkyQuest’s Abrasive Tools market report is excellent information for individuals interested in gaining insight into the valuable data, trends, and opportunities in a rapidly growing industry. Additionally, the report is written clearly and concisely, making it accessible to various audiences, from industry experts to market readers. Finally, one can gain an in-depth understanding of the primary and secondary market drivers, providing them with a comprehensive outlook of the current market situation and future projections. Westford, USA, April 03, 2023 (GLOBE NEWSWIRE) — SkyQuest forecasts that the Abrasive Tools market will experience a growth in value to USD 74.9 billion by 2030 at a CAGR of 5.62% during the forecast period (2022-2030), driven by increased demand from end users, advancements in technology and innovation,...

Continue reading

Assure Holdings Reports 2022 Year End Financial Results

DENVER, April 03, 2023 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, today reported financial results for the full year ended December 31, 2022. Key Financial Metrics (in thousands of USD) FY 2022 FY 2021 Gross Revenue $28,854   $36,583   Accounts Receivable Reserve   (17,878 )   (7,391 ) Revenue, net   10,976     29,192   Gross margin   (4,214 )   14,874   Total Operating Expenses   23,610     17,001   Net loss   (30,112 )   (2,756 ) Adjusted EBITDA*   (18,497 )   1,088   *See Explanation of Non-GAAP Financial Measures below for an explanation of Adjusted EBITDA and a reconciliation to GAAP financial measures Key Operational Metrics 4Q’22 4Q’21 FY 2022 FY 2021 Remote Neurology...

Continue reading

First Source Mortgage Fund Increases Monthly Distributions to Investors

TORONTO, April 03, 2023 (GLOBE NEWSWIRE) — Effective March 31, 2023, the First Source Mortgage Fund (“the Fund”) has increased the monthly distribution to investors from 62.5bps to 65bps. The result of this increase is a compounded annualized return of 8.03% for Class F units. The continued impressive performance of the Fund is a result of their best-in-class underwriting practices, an increasing interest rate environment, and the dedication of the highly experienced team of professionals who manage the fund. “We currently observe a healthy and robust alternative commercial mortgage market. The increasing interest rate environment has resulted in an influx of highly qualified deals that, fortunately for us, do not meet the stringent and inflexible requirements imposed by traditional lenders. We are open for new investor capital,...

Continue reading

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer

BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) —  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of INKmune™ to treat metastatic castration-resistant prostate cancer (mCRPC). “We believe this IND highlights the potential for INKmune™, our natural killer cell targeting immunotherapy, to treat solid tumors,” said RJ Tesi M.D., CEO of INmune Bio. “We believe INKmune™ provides a new treatment option that may allow men with mCRPC to safely avoid cytotoxic chemotherapy and potentially live longer.”  The trial is expected to take...

Continue reading

Fortinet to Announce First Quarter 2023 Financial Results

SUNNYVALE, Calif., April 03, 2023 (GLOBE NEWSWIRE) — News SummaryFortinet® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, announced that it will hold a conference call to discuss its first quarter 2023 financial results on Thursday, May 4, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Fortinet’s financial results conference call will be broadcast live in listen-only mode on the company’s investor relations website at http://investor.fortinet.com. While not required, it is recommended that you join at least 10 minutes prior to the event start. The CEO and CFO’s prepared remarks, supplemental slides and a call replay will be accessible from the Quarterly Earnings page on the Investor Relations page of Fortinet’s website at https://investor.fortinet.com/quarterly-earnings. About...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.